211 related articles for article (PubMed ID: 37544725)
21. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders.
Visconte V; Makishima H; Maciejewski JP; Tiu RV
Leukemia; 2012 Dec; 26(12):2447-54. PubMed ID: 22678168
[TBL] [Abstract][Full Text] [Related]
22. Spliceosome mutations in hematopoietic malignancies.
Hahn CN; Scott HS
Nat Genet; 2011 Dec; 44(1):9-10. PubMed ID: 22200771
[TBL] [Abstract][Full Text] [Related]
23. Biological relevance of alternative splicing in hematologic malignancies.
Szelest M; Giannopoulos K
Mol Med; 2024 May; 30(1):62. PubMed ID: 38760666
[TBL] [Abstract][Full Text] [Related]
24. Spliceosomal factor mutations and mis-splicing in MDS.
Hershberger CE; Daniels NJ; Padgett RA
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101199. PubMed ID: 33038983
[TBL] [Abstract][Full Text] [Related]
25. Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations.
Lee SC; North K; Kim E; Jang E; Obeng E; Lu SX; Liu B; Inoue D; Yoshimi A; Ki M; Yeo M; Zhang XJ; Kim MK; Cho H; Chung YR; Taylor J; Durham BH; Kim YJ; Pastore A; Monette S; Palacino J; Seiler M; Buonamici S; Smith PG; Ebert BL; Bradley RK; Abdel-Wahab O
Cancer Cell; 2018 Aug; 34(2):225-241.e8. PubMed ID: 30107174
[TBL] [Abstract][Full Text] [Related]
26. RNA splicing factors in normal hematopoiesis and hematologic malignancies: novel therapeutic targets and strategies.
Li Z; He Z; Wang J; Kong G
J Leukoc Biol; 2023 Feb; 113(2):149-163. PubMed ID: 36822179
[TBL] [Abstract][Full Text] [Related]
27. Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins.
Yoshimi A; Abdel-Wahab O
Clin Cancer Res; 2017 Jan; 23(2):336-341. PubMed ID: 27836865
[TBL] [Abstract][Full Text] [Related]
28. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.
Seiler M; Yoshimi A; Darman R; Chan B; Keaney G; Thomas M; Agrawal AA; Caleb B; Csibi A; Sean E; Fekkes P; Karr C; Klimek V; Lai G; Lee L; Kumar P; Lee SC; Liu X; Mackenzie C; Meeske C; Mizui Y; Padron E; Park E; Pazolli E; Peng S; Prajapati S; Taylor J; Teng T; Wang J; Warmuth M; Yao H; Yu L; Zhu P; Abdel-Wahab O; Smith PG; Buonamici S
Nat Med; 2018 May; 24(4):497-504. PubMed ID: 29457796
[TBL] [Abstract][Full Text] [Related]
29. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Pellagatti A; Boultwood J
Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
[TBL] [Abstract][Full Text] [Related]
30. Mechanistic Insights of Aberrant Splicing with Splicing Factor Mutations Found in Myelodysplastic Syndromes.
Kataoka N; Matsumoto E; Masaki S
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360561
[TBL] [Abstract][Full Text] [Related]
31. Dysregulated minor intron splicing in cancer.
Nishimura K; Yamazaki H; Zang W; Inoue D
Cancer Sci; 2022 Sep; 113(9):2934-2942. PubMed ID: 35766428
[TBL] [Abstract][Full Text] [Related]
32. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia.
Bamopoulos SA; Batcha AMN; Jurinovic V; Rothenberg-Thurley M; Janke H; Ksienzyk B; Philippou-Massier J; Graf A; Krebs S; Blum H; Schneider S; Konstandin N; Sauerland MC; Görlich D; Berdel WE; Woermann BJ; Bohlander SK; Canzar S; Mansmann U; Hiddemann W; Braess J; Spiekermann K; Metzeler KH; Herold T
Leukemia; 2020 Oct; 34(10):2621-2634. PubMed ID: 32358566
[TBL] [Abstract][Full Text] [Related]
33. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis.
Wang X; Song X; Yan X
Medicine (Baltimore); 2019 May; 98(21):e15743. PubMed ID: 31124956
[TBL] [Abstract][Full Text] [Related]
34. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
Patnaik MM; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
Am J Hematol; 2013 Mar; 88(3):201-6. PubMed ID: 23335386
[TBL] [Abstract][Full Text] [Related]
35. Recurrent SRSF2 mutations in MDS affect both splicing and NMD.
Rahman MA; Lin KT; Bradley RK; Abdel-Wahab O; Krainer AR
Genes Dev; 2020 Mar; 34(5-6):413-427. PubMed ID: 32001512
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Targeting of RNA Splicing in Cancer.
Bonner EA; Lee SC
Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510283
[TBL] [Abstract][Full Text] [Related]
37. Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis.
Inoue D; Bradley RK; Abdel-Wahab O
Genes Dev; 2016 May; 30(9):989-1001. PubMed ID: 27151974
[TBL] [Abstract][Full Text] [Related]
38. Splicing factor mutations and cancer.
Yoshida K; Ogawa S
Wiley Interdiscip Rev RNA; 2014; 5(4):445-59. PubMed ID: 24523246
[TBL] [Abstract][Full Text] [Related]
39. [Splicing factor mutations in myelodysplastic syndromes].
Shiozawa Y
Rinsho Ketsueki; 2018; 59(5):566-573. PubMed ID: 29877248
[TBL] [Abstract][Full Text] [Related]
40. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms.
Przychodzen B; Jerez A; Guinta K; Sekeres MA; Padgett R; Maciejewski JP; Makishima H
Blood; 2013 Aug; 122(6):999-1006. PubMed ID: 23775717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
